Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. - Wikidata - wikimedia - TriplyDB

Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

http://www.wikidata.org/entity/Q44092333

about

Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2 Mouse models of polyglutamine diseases: review and data table. Part I Genetics and neuropathology of Huntington's disease Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction Huntingtin and its role in neuronal degeneration Normal huntingtin function: an alternative approach to Huntington's disease Metabolism in HD: still a relevant mechanism?Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease Impaired brain creatine kinase activity in Huntington's disease.Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.A neuroprotective phase precedes striatal degeneration upon nucleolar stress.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.Age-associated chromatin relaxation is enhanced in Huntington's disease mice.Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression Huntington disease models and human neuropathology: similarities and differences CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.Body composition in premanifest Huntington's disease reveals lower bone density compared to controls Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alpha In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice.Skeletal muscle pathology in Huntington's disease PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease Dominant effects of the Huntington's disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategy Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.

P2860

Q24562763-D52931A2-49C6-47FF-B7B5-59997EF10586 Q24618141-A62B9390-B182-47D2-870C-070F46B8A4B3 Q24681194-CD28E911-B8DD-4441-BAC5-FFD825BE328B Q26853025-877286E6-66D4-4A2B-95B6-3E90C307C77B Q27023050-66B1FEC1-4461-43A1-9947-E6C631E41902 Q27026549-98D55F37-984E-47A2-BB33-319C54AB6C10 Q27311425-56C24D32-2790-4726-81BD-AAE5762E5B1E Q27341821-65CC4CF0-82CA-481E-8029-6DF89A033526 Q28281434-3AC39732-7016-446D-B185-779D8D95FCF2 Q28281904-663794CC-4580-48AD-952D-6F8373F35BF9 Q28394301-E2C10841-D87E-4F7B-B699-CEDB4D831A7F Q28479035-5DE065AD-B200-44A4-999B-6BB3EE34F35F Q28507529-A49BB1B4-E5F3-4849-A24B-B0B70D5580E6 Q28743929-F898CDF6-D449-4C67-8433-BFCD19F5017E Q30468147-10921805-E1CB-4BAE-850A-CCDF47196359 Q30480013-5B9F462E-6E8C-4565-8D87-37EC59A9AAD4 Q30549660-E1E4E938-3767-40FB-96A9-93633E665954 Q31002507-F096BE4B-8C0D-4221-9B44-392346C5BD58 Q31129663-DD45535F-234C-40C7-A0EF-16065E8F2E5F Q33562672-39137BD2-D3EF-4F67-BE33-821D850DDDBD Q33563614-6F728597-8F8A-4124-A48A-D692A39B58CD Q33663335-AB74132A-E88C-44C1-87FC-A6A8728D71B4 Q33755822-D0C25677-8525-49D1-B704-DCFE20F92E7C Q33755845-E3C5EC97-A709-4FE6-970A-A0948C095625 Q33760994-7C2E2C0E-096E-437A-BA55-53BA70DA1877 Q33773689-79FB40E7-8F09-4C48-89FB-B0B061EF9D46 Q33838303-EA779D41-9DA6-46D0-B731-D2D5921918A7 Q33911613-4B13860B-B9AE-4FF9-BDE0-6ECDC03FB46B Q33922914-91987C66-17C2-43AF-99C8-C5485DFEA965 Q33980357-BCFD15B3-677B-40BA-BF99-7B622B71EA47 Q34011801-341317D6-A6AF-407C-9F04-D1C63BAF8ECE Q34042260-5622990A-9DEC-45D3-8C69-E958F276E8DF Q34060224-22248E8B-8566-4588-AC37-D65569537F8B Q34292092-7A1E1905-100D-4A7A-B742-DFEBBFFD40B4 Q34383492-2130B7D7-2527-4251-99CA-6934798B65ED Q34391101-130AF07B-1811-472A-80D5-BFD64C4CEE97 Q34409630-BB298029-E49B-422B-B16D-069710E6DD16 Q34675885-C3F5E855-F0C1-4366-B646-BFAD81E62599 Q34763178-A013476B-6893-4DEB-A3E2-5ACCE4A51178 Q34994779-C0A18331-819F-4599-B076-CCA840CE2013

P2860

Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

http://www.wikidata.org/entity/Q44092333

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Dysregulation of gene expressi ...... l changes in muscle and brain.

@en

Dysregulation of gene expressi ...... l changes in muscle and brain.

@nl

type

label

Dysregulation of gene expressi ...... l changes in muscle and brain.

@en

Dysregulation of gene expressi ...... l changes in muscle and brain.

@nl

prefLabel

Dysregulation of gene expressi ...... l changes in muscle and brain.

@en

Dysregulation of gene expressi ...... l changes in muscle and brain.

@nl

P1433

Q44092333-805C0C71-402E-4BCA-B582-8608ACBE78B1

P1476

Q44092333-41F6B06B-D52E-4421-AEBF-2E99EC1C7442

P2093

Q44092333-2CD76921-5358-4BBF-AC55-6CC9C6E97CCA

Q44092333-401ED0A0-3AC0-4EA2-A045-4BF7EC56B7D6

Q44092333-49C0F581-687E-4694-915B-DB1D893CCF31

Q44092333-4B2C52C3-2BD5-4DEA-9E89-80883372CFA5

Q44092333-7C544998-0928-438E-8CCF-3A53316EA883

Q44092333-80A88A35-2B38-4913-8597-6C91BBE9F154

Q44092333-871A767F-0D82-4B6B-B053-BCC9AA2A7F0B

Q44092333-A1694EFF-E29A-43FC-99DA-03AD429EFEF8

Q44092333-C4387BE0-A6FE-4638-AADB-26469F9B57F6

Q44092333-C4E1A34B-CCA1-4EDC-A05B-8959FEC0D7A2

P304

Q44092333-9C476EE0-59A8-4BE3-BD22-307CF980076C

P31

Q44092333-B5D79090-8DD8-44F9-AC1D-31506327D08B

P356

Q44092333-F229C897-3F17-4908-A3E4-AC7AFB5F9A1E

P433

Q44092333-B898C963-E6D7-4407-AF34-294289270A93

P478

Q44092333-2945C753-70E7-4C6C-B8ED-5A75BCDBFBCE

P50

Q44092333-16688858-B5DF-4465-B41F-0130822F167F

Q44092333-6C42C91B-8364-452C-9E45-D9984BB33E55

P577

Q44092333-DC1CB8AC-2A06-43F8-9A04-F971EB8F794C

P5875

Q44092333-A7D25F3E-32D4-4AE9-86F2-83A56945B3D8

P698

Q44092333-762DB572-01D1-48A3-B75F-8F9D3227B7F0

P356

P1433

Human Molecular Genetics

P1476

Dysregulation of gene expressi ...... l changes in muscle and brain.

@en

P2093

Andrew D Strand

http://www.w3.org/2001/XMLSchema#string

Anne B Young

http://www.w3.org/2001/XMLSchema#string

Annette M Woods

http://www.w3.org/2001/XMLSchema#string

Dimitri Krainc

http://www.w3.org/2001/XMLSchema#string

Donald A Bergstrom

http://www.w3.org/2001/XMLSchema#string

Edmond Y Chan

http://www.w3.org/2001/XMLSchema#string

James M Olson

http://www.w3.org/2001/XMLSchema#string

Nikki L Peters

http://www.w3.org/2001/XMLSchema#string

Sarah A Hanson

http://www.w3.org/2001/XMLSchema#string

Stephen J Tapscott

http://www.w3.org/2001/XMLSchema#string

P304

1911-1926

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/11.17.1911

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Charles Kooperberg

Ruth Luthi-Carter

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11220450

http://www.w3.org/2001/XMLSchema#string

P698

12165554

http://www.w3.org/2001/XMLSchema#string